You've never glowed like this before: the $75 golden face mask that's about to go viral
Antipodes has done it again. The cult Kiwi skincare brand is back with a shimmering, skin-loving showstopper that's set to replace every sheet mask in your bathroom drawer.
The Aura Gold Mānuka Honey Radiance Mask isn't just skincare, it's a weekly golden ritual. And it really is gold.
Launching nationally on June 2nd, this decadent vitamin C-powered treatment is already generating buzz from beauty editors and skincare sleuths alike.
At $75 for 75ml, it's worth the price tag, as it might just be the one that finally delivers that elusive 'glow from within' look without a facialist on speed dial.
So what makes this creamy mask a contender for cult status?
What's inside the gold
For starters, Aura Gold is powered by export-grade New Zealand mānuka honey, ethically sourced from Grafter's Honey, a sustainable bee farm literally next door to Antipodes' founder Elizabeth Barbalich.
Combined with Kakadu plum (which boasts one of the highest concentrations of vitamin C in nature), this mask is a glow-up in a tube.
You'll also find plant-based hyaluronic acid to plump, ceramides to support your skin barrier, and gentle lime caviar AHAs that exfoliate and boost collagen production.
Skin that feels fresh, hydrated, and noticeably more radiant.
Oh, and did we mention the texture? It's buttery, velvety, and golden, like applying a very fancy custard to your face. In the best way.
But does it actually work?
According to a four-week in-vivo trial, 98 per cent of users agreed it felt luxurious, and 87 per cent said their skin looked visibly more radiant.
Those are the kind of numbers that usually come with high-end spa treatments, not an at-home mask.
It's also housed in recyclable aluminium packaging with FSC-certified outer packaging, so your skin and the planet both get a little love.
Why you'll be seeing this all over your feed
Aura Gold fits right into the soft life trend that's dominating your TikTok 'For You' page, think less hustle, more pampering, slow beauty rituals, and skincare that feels indulgent and intelligent.
It's the kind of product you pull out on a Sunday night when your skin needs a reset and your brain needs a break.
It gives expensive without the spa bill.
And while it may look pretty on your vanity (and it does), this mask backs up the aesthetic with science-led ingredients and visible results.
Whether you're treating yourself, hunting for the perfect gift, or replacing your go-to sheet mask stash with something smarter and more sustainable, Aura Gold might just become your next skincare non-negotiable.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
West Australian
5 days ago
- West Australian
Larkham wants proof Brumbies on track for Super title
Coach Stephen Larkham has no qualms about bringing Brumbies captain Allan Alaalatoa back from injury to face the Hurricanes despite the possibility of the Super Rugby Pacific qualifying final being a dead rubber. Alaalatoa missed their final-round loss to the Crusaders with a calf strain, but Larkham says his leadership is vital as the Brumbies look to see off the Hurricanes on Saturday night in Canberra. "He's had a good week so ticked everything off in terms of all the rehab markers with his strength, running, contact so he's ready to go," Larkham said of the Wallabies prop. "He's always been an outstanding rugby player but the leadership qualities that he brings to the team, the confidence that he gives the other players is certainly something that we're going to benefit from this weekend." In a quirk of the new six-team finals system and the scheduling of the finals, the third-placed Brumbies will know before kick-off whether they have a place in the semi-finals. There are three qualifying finals and all winners plus the top-ranked loser will advance. But Larkham said the Brumbies wanted to field their best team available and target a win regardless of the outcome of the other matches. "We are the last game this weekend but we've been pretty firm on making sure that we get a good performance out there on the field so irrespective of the other results we need to know that we're playing well," the coach said on Wednesday. "We can't get distracted by these other games and the other results. "The most important thing for us right now is to focus on our preparation so that we can have our best performance this weekend and either way we're going out there to try and win the game." In the only change to the starting side, Feao Fotuaika, who scored in the 33-31 loss to the Crusaders, will make way for Alaalatoa and return to the bench, bumping Rhys Van Nek out of the squad. Larkham said his team wanted a better first half after they trailed the Crusaders 14-25 at halftime while they were also down at the break in their last clash with the Hurricanes, which they also lost. He said with the Kiwi teams playing a similar fast and physical style, the Brumbies would be ready. "They're a physical side, the contests at the breakdown are very similar to Crusaders," Larkham said. "They're very good with the ball in hand, they've got dangerous threats around the ruck ... and they've got the ability to shift the ball quite well. "We've come across teams that play this way a few times this year and hopefully that's put us in a good position to play well this weekend." Brumbies: James Slipper, Billy Pollard, Allan Alaalatoa, Nick Frost, Tom Hooper, Rob Valetini, Rory Scott, Tuaina Taii Tualima, Ryan Lonergan, Noah Lolesio, Corey Toole, David Feliuai, Len Ikitau, Andy Muirhead, Tom Wright. Reserves: Lachlan Lonergan, Lington Ieli, Feao Fotuaika, Lachlan Shaw, Luke Reimer, Harrison Goddard, Declan Meredith, Ollie Sapsford. Hurricanes: Xavier Numia, Asafo Aumua, Tyrel Lomax, Zach Gallagher, Caleb Delany, Devan Flanders, Du'Plessis Kirifi, Peter Lakai, Cam Roigard, Brett Cameron, Fatafehi Fineanganofo, Peter Umaga-Jensen, Billy Proctor, Bailyn Sullivan, Ruben Love. Reserves: Raymond Tuputupu, Tevita Mafileo, Pasilio Tosi, Hugo Plummer, Brad Shields, Ereatara Enari, Ngatungane Punivai, Callum Harkin.
News.com.au
30-05-2025
- News.com.au
Family of teenager who died playing ‘run it straight' make heartbreaking revelation
The family of Ryan Satterthwaite, who tragically died from injuries sustained in a backyard 'run it straight' game, has revealed the teenager and his friends got the idea to play the game after seeing it online. For years the 'run it straight' trend has sporadically gone viral on social media platforms. But in recent months it has transformed from a viral social media trend to a fully-fledged sport, with 'Run it Straight Official' and 'RUNIT Championship League' turning it into a business and holding competitions in Australia and New Zealand. The sport involves four rounds of players charging at each other along a 10m grass runway, with each competitor taking turns carrying a rugby ball. The objective is to either successfully tackle the opponent or run them over in a hard-hitting collision. The contest ends when a player is knocked out or concussed. If both players remain standing at the end of four rounds, a judging panel decides the winner, with the key criteria judged being damage to your opponent. But the 'sport' has been controversial due to the violent nature of some of the tackles, as leading neuroscientists warn 'people will die'. And that grave warning has now rang true, with Kiwi teenager Ryan Satterthwaite dying from what was described as an 'innocuous' tackle playing a backyard game of 'run it straight' on the weekend. According to Ryan's uncle, Peter Satterthwaite, his nephew and his friends decided to try it at a 21st birthday celebration on Sunday after seeing the big hits on social media. 'They decided to give it a go because of what they saw on social media and on the news last week about it,' Satterthwaite told Stuff. Footage of the tackle that resulted in the injuries that would later take the life of Ryan, was given to police. The video of the tackle in question reportedly didn't even hit his head, instead it was the jolting motion of the hit that proved fatal. Satterthwaite says in the aftermath of the game, his nephew was coherent and talking with his friends but soon deteriorated at a rapid rate. An ambulance was called to the home in Palmerston North but he went downhill at such a rate, his friends decided they couldn't wait for it to arrive, rushing him to Palmerston North Hospital. By the time they arrived Ryan had lost consciousness due to the swelling on his brain. He would never wake up. Dr Alan Pearce warns 'it will happen again' Leading sports neuroscientist Dr Alan Pearce told that it was sadly 'only a matter of time' until someone died playing the sport. 'This was a matter of time really as sad as that is to say,' Dr Pearce told on Tuesday. 'The concern is that this can happen at any level. Even in the sanctioned 'run it' events someone will probably die in that at some point as well. 'It can't be done safely and when there's kids and teens that see it they like to copy what they see online, and this is something that absolutely not should be copied. 'It is the biggest please do not try this at home disclaimer if I've ever seen one'. That message was echoed by Satterthwaite, who told Stuff: 'We can put it all out on social media that this is a silly thing to do. Don't do it but no-one's going to listen to us unless we get celebrities on board.' After the teen's death made waves RUNIT Championship League organisers released a statement saying they did 'not encourage any copying of the sport as it should only be done under the strict conditions'. 'This is tragic news and our hearts go out to the family and friends of Ryan. Any contact sport like boxing, martial arts or combat-style activities should only be held in highly-controlled environments, which include professional medical supervision and support.' But that response only infuriated Peter Satterthwaite who said that they are 'dumb' if they think that would stop another fatality from happening. 'That's just their bullsh** line to justify what they're trying to do,' he continued. 'What did they think was going to happen? They'd be dumb if they thought nobody was going to get hurt. They said on the news they have a medical professional on standby. But a medical professional wouldn't have helped Ryan one little bit.' New Zealand rugby stars urge caution amid tragic death On Wednesday night, New Zealand Rugby League (NZRL) issued a statement, saying: 'NZRL is not associated with nor encourages participation in any events or collision sports like Runit.' 'It's concerning to see people in these events putting themselves at risk of serious injury, and we strongly encourage our rugby league community to only participate in games or events organised or sanctioned by NZRL, our zones and districts, or our associates,' the statement continued. 'In doing so, we can control and mitigate the health and safety of all involved.' While New Zealand rugby stars urged people to not participate in the violent sport. Former All Black halfback Steve Devine told Radio NZ the game was a 'recipe for disaster' and believes it should be banned. While All Blacks star Ardie Savea admitted he had participated in something similar during his youth and said it was therefore hard to condemn it without being a hypocrite. 'It's a tough one,' Ardie Savea said at Moana Pasifika training on Thursday. 'I don't know the precautions they take in terms of the head side of things and you can see the other side and understand why they're doing it and whatnot. 'It's hard because it's kind of made me the rugby player I am – I used to do run it straights in the backyard with Bus (brother Julian Savea) – so you kind of see both sides. 'It's really hard to say, but I'd just encourage people to be safe.' New Zealand government moves to crack down on controversial spot The future of 'run it straight' now hangs in the balance in New Zealand, with the Government seeking advice on what they can do about the controversial sport. Sport NZ group chief executive Raelene Castle told the New Zealand Herald it was concerned about the emergence of the sport, 'which clearly comes with significant health and safety risks'. 'Both Sport NZ and High-Performance Sport NZ (HPSNZ) are committed to fostering safe and inclusive activities and events for all New Zealanders. 'We are working to facilitate a cross-agency discussion with those who have an interest in this area on what a Government approach to the operation of combat sport, including the emergence of activities and events like run it straight, in New Zealand could look like.' Castle strongly advised people against participating in run it or any activities that encourage high-speed collisions. While New Zealand Prime Minister Christopher Luxon labelled Satterthwaite's death an 'absolute tragedy' on Friday morning and said competing in the viral trend was 'a dumb thing to do'. 'When it's happening at a 21st birthday party unofficially, that is not something the Government can solve through legislation or through regulation,' Luxon said. 'All I can say to young adults who are participating is you've got some personal responsibility in this. You're hearing the advice from the police, from the medical fraternity, from the Government, from principals saying don't do it. 'To the adults that are involved in the more formal organisation of it and are influencing it and leading this out on social media, I think you need to stop and I can't be any clearer. 'The evidence is that it's a dumb thing to do and you should stop.'
News.com.au
29-05-2025
- News.com.au
Health Check: Aroa's ‘hero' product propels the wound management house back into black
Aroa shares surge 13% after the company's full-year results exceeded guidance New wound management IPO does the rounds for $35 million Inoviq shares vault up to 58% on early cancer light therapy results Kiwi-based wounds management house Aroa Biosurgery (ASX:ARX) has exceeded its recent revenue and earnings guidance, after a robust second half on the back of its 'hero' Myriad product range. Aroa's revenue came in at NZ$84.7 million for the year to March 2025, 23% higher and slightly above the NZ$81-84 million range the company guided to in late April. Normalised earnings before interest tax depreciation and amortisation (ebitda) were NZ$4.2 million, compared with the previous NZ$3.1 million loss. Once again, the number was a tad above the guided range of NZ$2-4 million. Aroa has also guided to current-year revenue of NZ$92-100 million, 10-20% higher year on year, with ebitda of NZ$5-8 million. CEO Brian Ward stresses the company's 'star product' Myriad has been delivering the goods, with sales up 35%. Myriad is used for complex wounds including trauma and lower limb salvage. Sold via Aroa's partner TELA Bio, sales of its hernia and breast reconstruction tool Ovitex rose 22% Sales of the Endoform wound dressing were flat, as expected. Expanding indications Ward said the company would focus on expanding indications for its products, which are biological materials sourced from ovine intestines. This push is being supported by several clinical studies, such as a lower limb salvage study trial that resulted in quick healing with no complications. 'That's quite different to what we have seen with other technologies,' he says. However, Aroa has 'paused' the rollout of its Symphony product, for hard-to-heal wounds such as diabetic ulcers. This is because the company has won inpatient reimbursement in the US, but not coverage for physicians. The company plans a supportive trial to win full reimbursement. 'The rules are changing and only products with randomised, controlled trials will be reimbursed,' Ward says. 'This will take many rivals out of the market.' Aroa has product approvals across 50 countries, but almost all its revenue derives from the US. CFO James Agnew said the US tariff impact on the company was likely to be around NZ$1.5 million, or around 1% of revenue. Because of transfer pricing arrangements between TELA Bio and Aroa's own US entity, that's far less than the blanket 10% rate Uncle Sam levies on NZ goods. New wound play does the IPO rounds Still on wound management, Tetraherix is defying the barren IPO biotech landscape with a $35 million raising to advance its novel tools for applications including tissue healing, bone regeneration and surgical spacing. Invented by chemical engineer and University of Sydney researcher Dr Ali Fathi, the platform-based tech is the world's first 'biostealth fluid matrix'. Supplied in ready-to-use syringes, the polymer is injected into the relevant anatomy and sets to a 'chewing-gum' consistency that can be easily moulded to suit the application. Eventually, the material breaks down into water and carbon dioxide. Pending expected US Food and Drug Approval, the company hopes to bring its first products to market in the first half of 2026. These are for dental applications and bone regeneration and orthopaedic uses. The company also has tools in the pipeline for scar prevention during surgery and a prostate surgery 'spacer' to protect surrounding tissue (such as the rectum) during radiation therapy. Doing the rounds Joint lead managers Morgans and Barrenjoey are undertaking the institution round which closes next Tuesday, with a limited retail offering open until June 17. The company is expected to list in late June. The shares are offered at $2.88 a pop, amounting to a $155 million market cap and a $115 million enterprise value (allowing for cash on hand). The founder of 'cloud' accounting software giant Xero, Rod Drury is a notable investor. Invion lights up on skin cancer trial The developer of photodynamic therapies (PTDs) for cancers, Invion (ASX:IVX) has passed the initial safety test for its phase I/II non-melanoma skin cancer trial, being carried out in Queensland (of course). A safety review committee found no 'adverse events' among the first treated patients, who were administered Invion's candidate INV-043 as an ointment. What's more, 'early indications show an observable reduction in the lesion size after a single treatment cycle'. Clinician feedback shows patients did not experience any pain during the treatment, 'which compares favourably to currently approved PDT treatments.' By combining oxygen and light, PTDs are known to kill malignant cells and shut down tumors. Known about for more than a century, the science is supported by more than 500 trials. That said, it's been an overlooked area of oncology and Invion is the only listed exemplar. Invion now is proceeding to the second stage of the adaptive trial, which involves dose optimalisation. Meanwhile, the safety data will influence the company's upcoming phase I/II trial for ano-genital cancer, in alliance with the Peter MacCallum Cancer Centre. Known for wild movements, Invion shares soared up to 58% this morning. Inoviq share freeze highlights disclosure dilemmas A quirky aspect of clinical results is they are not validated until they are presented in a prestigious peer-reviewed publication, or a conference of luminaries. Typically, a company will post top-line results earlier and this can lead to investor confusion about what's new and what's merely additional info for the boffins. On Monday, the ASX suspended share trading in cancer drug developer Inoviq (ASX:IIQ) and queried why the company's shares soared 25%, from 37 cents on Wednesday May 21, to last Friday's high of 46.5 cents. Inoviq yesterday pointed to an abstract poster presentation for an upcoming American Society of Clinical Oncology (ASCO) conference published online. This outlined 'the background, methods, results and conclusions underpinning the high-level results' of an independent patient validation study of the company's ovarian cancer test. The results of the blood test were 'outstanding', with more than 94% accuracy. Hold the front page! Okay, let it go: the guts of the results were outlined on December 3 last year – and referred to in subsequent ASX disclosures. Inoviq says: 'some shareholders may have missed or misunderstood the significance of and may believe the abstract contains new or better information, which is materially price sensitive.' The company believes that was not the case and did not 'announce' the abstract to the ASX. Fair enough! After all, there's nothing more frustrating than companies hyping up presentations that contain no genuine news. In old tabloid terms it's known as a Bamix job: a beat up. But like all good tabloid yarns, there's a twist: Inoviq will present further trial information that is price sensitive, to the ASCO powwow in Chicago on Sunday. This prezzo is under embargo until that day and Inoviq plans to announce the 'tightly held' information first thing on Monday. In the meantime, it's best the shares remain untradeable.
